{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-315918","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.452930+00:00","generated_at":"2026-05-16T13:33:24.455597+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026","bullets":["Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.","Three Phase 2 data readouts expected in 2026: EVO756 CSU (1H26), EVO756 AD (2H26), EVO301 AD (1H26).","Q3 2025 revenue $10.0M from Maruho collaboration; zero in prior-year quarter.","Net loss improved to $12.5M vs $15.9M YoY; cash and investments $76.0M as of Sep 30, 2025.","R&D expenses increased to $19.6M from $13.3M YoY, reflecting pipeline advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-315918","json":"https://secwatch.observer/filing/0001193125-25-315918.json","markdown":"https://secwatch.observer/filing/0001193125-25-315918.md","text":"https://secwatch.observer/filing/0001193125-25-315918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/0001193125-25-315918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-20251211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:33:24.455597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}